156
Views
3
CrossRef citations to date
0
Altmetric
Rheumatoid Arthritis

Clinical characteristics and social productivity levels of patients with malignant rheumatoid arthritis based on a nationwide clinical database in Japan: annual survey from 2003 to 2013

, , , , , , , & show all
Pages 621-628 | Received 19 Mar 2020, Accepted 30 Jun 2020, Published online: 31 Jul 2020

References

  • Bevans M, Nadell J, Demartini F, Ragan C. The systemic lesions of malignant rheumatoid arthritis. Am J Med. 1954;16(2):197–211.
  • Aikawa T, Yoshizawa H. Rheumatoid vasculitis and malignant rheumatoid arthritis. Nippon Rinsho. 1985;43(10):2065–9.
  • Matsumoto Y. The rheumatoid vasculitis and malignant rheumatoid arthritis(MRA). Nippon Rinsho. 2002;60(12):2408–16.
  • Sparks JA. Rheumatoid arthritis. Ann Intern Med. 2019;170(1):ITC1–itc16.
  • Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8.
  • Guidelines for the management of rheumatoid arthritis, Japan College of Rheumatology. 2014, ed. Osaka: Medical Review Co., Ltd.; 2014.
  • Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, et al.; British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group. British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford). 2006;45(9):1167–9.
  • Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford). 2009;48(4):436–9.
  • Kishore S, Maher L, Majithia V. Rheumatoid vasculitis: a diminishing yet devastating menace. Curr Rheumatol Rep. 2017;19(7):39.
  • Makol A, Matteson EL, Warrington KJ. Rheumatoid vasculitis: an update. Curr Opin Rheumatol. 2015;. 27(1):63–70.
  • Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659–62.
  • Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore). 1981;60(4):288–97.
  • Kato E, Sawada T, Tahara K, Hayashi H, Tago M, Mori H, et al. The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis. 2017;20(7):839–45.
  • Doyle TJ, Dellaripa PF. Lung manifestations in the rheumatic diseases. Chest 2017;152(6):1283–95.
  • Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544–54.
  • Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, T2T Expert Committee, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7.
  • Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med. 1991;151(11):2249–54.
  • Abel T, Andrews BS, Cunningham PH, Brunner CM, Davis JSt, Horwitz DA. Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes. Ann Intern Med. 1980;93(3):407–13.
  • Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76(3):377–84.
  • Makol A, Crowson CS, Wetter DA, Sokumbi O, Matteson EL, Warrington KJ. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology (Oxford). 2014;53(5):890–9.
  • Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, Guillevin L. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002;41(10):1126–32.
  • Puéchal X, Miceli-Richard C, Mejjad O, Lafforgue P, Marcelli C, Solau-Gervais E, et al.; Club Rhumatismes et Inflammation (CRI). Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis. 2008;67(6):880–4.
  • Josselin L, Mahr A, Cohen P, Pagnoux C, Guaydier-Souquieres G, Hayem G, et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis. 2007;67(9):1343–6.
  • Assmann G, Pfreundschuh M, Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clin Exp Rheumatol. 2010;28(1 Suppl 57):81–3.
  • Puechal X, Gottenberg JE, Berthelot JM, Gossec L, Meyer O, Morel J, Investigators of the AutoImmunity Rituximab Registry, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry. Arthritis Care Res (Hoboken). 2012;64(3):331–9.
  • Hellmann M, Jung N, Owczarczyk K, Hallek M, Rubbert A. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47(6):929–30.
  • Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63 (Suppl 5):v1–58.
  • Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–6.
  • Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. Rheumatology (Oxford). 2017;56(8):1348–57.
  • Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014;19(3):353–9.
  • Fernández-Díaz C, Loricera J, Castañeda S, López-Mejías R, Ojeda-García C, Olivé A, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum. 2018;48(1):22–7.
  • Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003;30(10):2287–91.
  • Saint Marcoux B, Bandt MD,; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006;73(6):710–3.
  • Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S23–S9.
  • Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2012;87(8):739–45.
  • Nyhall-Wahlin BM, Petersson IF, Jacobsson C, Geborek P, Nilsson JA, Nilsson K, et al. Extra-articular manifestations in a community-based sample of patients with rheumatoid arthritis: incidence and relationship to treatment with TNF inhibitors. Scand J Rheumatol. 2012;41(6):434–7.
  • Negoescu AF, Tennekone D, Soljak MA, Abraham SM. Extraarticular manifestations of rheumatoid arthritis develop in patients receiving anti-tumor necrosis factor-α treatment: a retrospective chart review from a UK center. J Rheumatol. 2014;41(10):1944–7.
  • Richette P, Dieude P, Damiano J, Liote F, Orcel P, Bardin T. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol. 2004;31(10):2079–81.
  • Fujikawa K, Kawakami A, Hayashi T, Iwamoto N, Kawashiri SY, Aramaki T, et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol. 2010;20(1):86–9.
  • Theander L, Nyhall-Wahlin BM, Nilsson JA, Willim M, Jacobsson LTH, Petersson IF, et al. Severe extraarticular manifestations in a community-based cohort of patients with rheumatoid arthritis: risk factors and incidence in relation to treatment with tumor necrosis factor inhibitors. J Rheumatol. 2017;44(7):981–7.
  • Terreaux W, Masson C, Eschard JP, Bardin T, Constantin A, Dantec LL, et al. Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: data from the French registry REGATE. Joint Bone Spine. 2018;85(1):53–7.
  • Tanaka E, Inoue E, Hoshi D, Shimizu Y, Kobayashi A, Sugimoto N, et al. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Mod Rheumatol. 2015;25(4):503–13.
  • Emery P, Smolen JS, Ganguli A, Meerwein S, Bao Y, Kupper H, et al. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. Rheumatology (Oxford). 2016;55(8):1458–65.
  • Curtis JR, Winthrop K, O'Brien C, Ndlovu MN, de Longueville M, Haraoui B. Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment. Arthritis Res Ther. 2017;19(1):276.
  • Tanaka E, Inoue E, Yamaguchi R, Shimizu Y, Kobayashi A, Sugimoto N, et al. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan. Mod Rheumatol. 2017;27(2):227–36.
  • Weyand CM, Schmidt D, Wagner U, Goronzy JJ. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum. 1998;41(5):817–22.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.